Example of Medical Oncology format
Recent searches

Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format Example of Medical Oncology format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Medical Oncology — Template for authors

Publisher: Springer
Categories Rank Trend in last 3 yrs
Hematology #24 of 123 -
Oncology #84 of 340 up up by 4 ranks
Cancer Research #80 of 207 down down by 2 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 541 Published Papers | 3389 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 02/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

Nature

Quality:  
High
CiteRatio: 16.0
SJR: 4.539
SNIP: 2.28
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 15.8
SJR: 4.103
SNIP: 1.983
open access Open Access
recommended Recommended

American Association for Cancer Research

Quality:  
High
CiteRatio: 18.2
SJR: 5.427
SNIP: 2.243
open access Open Access

American Association for Cancer Research

Quality:  
High
CiteRatio: 8.7
SJR: 2.273
SNIP: 1.157

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

2.834

13% from 2018

Impact factor for Medical Oncology from 2016 - 2019
Year Value
2019 2.834
2018 3.252
2017 2.92
2016 2.634
graph view Graph view
table view Table view

6.3

9% from 2019

CiteRatio for Medical Oncology from 2016 - 2020
Year Value
2020 6.3
2019 5.8
2018 5.6
2017 5.9
2016 5.8
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 13% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 9% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.037

3% from 2019

SJR for Medical Oncology from 2016 - 2020
Year Value
2020 1.037
2019 1.004
2018 0.988
2017 0.757
2016 0.832
graph view Graph view
table view Table view

0.989

14% from 2019

SNIP for Medical Oncology from 2016 - 2020
Year Value
2020 0.989
2019 0.866
2018 0.882
2017 0.847
2016 0.825
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 3% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 14% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Medical Oncology

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Springer

Medical Oncology

Approved by publishing and review experts on SciSpace, this template is built as per for Medical Oncology formatting guidelines as mentioned in Springer author instructions. The current version was created on and has been used by 243 authors to write and format their manuscripts to this journal.

i
Last updated on
01 Jul 2020
i
ISSN
1606-8610
i
Open Access
Hybrid
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Citation Type
Author Year
(Blonder et al, 1982)
i
Bibliography Example
Beenakker CWJ (2006) Specular andreev reflection in graphene. Phys Rev Lett 97(6):067,007, URL 10.1103/PhysRevLett.97.067007

Top papers written in this journal

Journal Article DOI: 10.1007/S12032-011-0004-Z
Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation
Ming-Chun Lai1, Zhe Yang1, Lin Zhou1, Qian-qian Zhu1, Haiyang Xie1, Feng Zhang1, Liming Wu1, Leiming Chen1, Shusen Zheng1
01 Sep 2012 - Medical Oncology

Abstract:

Metastasis-associated lung adenocarcinoma transcript 1(MALAT1), a long non-coding RNA (lncRNA), is up-regulated in many solid tumors and associated with cancer metastasis and recurrence. However, its role in hepatocellular carcinoma (HCC) remains poorly understood. In the present study, we evaluated the expression of MALAT1 b... Metastasis-associated lung adenocarcinoma transcript 1(MALAT1), a long non-coding RNA (lncRNA), is up-regulated in many solid tumors and associated with cancer metastasis and recurrence. However, its role in hepatocellular carcinoma (HCC) remains poorly understood. In the present study, we evaluated the expression of MALAT1 by quantitative real-time PCR in 9 liver cancer cell lines and 112 HCC cases including 60 cases who received liver transplantation (LT) with complete follow-up data. Moreover, small interfering RNA (siRNA) was used to inhibit MALAT1 expression to investigate its biological role in tumor progression. We found that MALAT1 was up-regulated in both cell lines and clinical tissue samples. Patients with high expression level of MALAT1 had a significantly increased risk of tumor recurrence after LT, particularly in patients who exceeded the Milan criteria. On multivariate analysis, MALAT1 was an independent prognostic factor for predicting HCC recurrence (hazard ratio, 3.280, P = 0.003).In addition, inhibition of MALAT1 in HepG2 cells could effectively reduce cell viability, motility, invasiveness, and increase the sensitivity to apoptosis. Our data suggest that lncRNA MALAT1 play an important role in tumor progression and could be a novel biomarker for predicting tumor recurrence after LT and serve as a promising therapeutic target. read more read less

Topics:

Tumor progression (61%)61% related to the paper, Milan criteria (57%)57% related to the paper, Adenocarcinoma (54%)54% related to the paper, MALAT1 (54%)54% related to the paper, Transplantation (54%)54% related to the paper
543 Citations
Journal Article DOI: 10.1007/S12032-010-9536-X
Physical activity and survival after breast cancer diagnosis: meta-analysis of published studies
01 Sep 2011 - Medical Oncology

Abstract:

Published data have shown that physical activity (PA) has a positive role on the primary prevention of breast cancer risk However, the role of PA on breast cancer outcome has been controversial with inconsistent data The lack of a meta-analysis that addresses that issue prompted the current report A comprehensive literature s... Published data have shown that physical activity (PA) has a positive role on the primary prevention of breast cancer risk However, the role of PA on breast cancer outcome has been controversial with inconsistent data The lack of a meta-analysis that addresses that issue prompted the current report A comprehensive literature search identified eight studies, of which two studies were excluded The remaining six studies (12,108 patients with breast cancer) were included in this meta-analysis Pre-diagnosis PA reduced all causes mortality by 18% but had no effect on breast cancer deaths Post-diagnosis PA reduced breast cancer deaths by 34% (HR = 066, 95% CI, 057–077, P < 000001), all causes mortality by 41% (HR = 059, 95% CI, 053–065, P < 000001), and disease recurrence by 24% (HR = 076, 95% CI, 066–087, P = 000001) Breast cancer mortality was reduced by pre-diagnosis PA in women with body mass index (BMI) < 25 kg/m2, while post-diagnosis PA reduced that risk among those with BMI ≥ 25 kg/m2 On the other hand, post-diagnosis PA reduced all causes mortality regardless of the BMI The analysis showed that post-diagnosis PA reduced breast cancer deaths (HR = 050, 95% CI, 034–074, P = 00005), and all causes mortality (HR = 036, 95% CI, 012–103, P = 006) among patients with estrogen receptor (ER)-positive tumor, while women with ER-negative disease showed no gain The current meta-analysis provides evidence for an inverse relationship between PA and mortality in patients with breast cancer and supports the notion that appropriate PA should be embraced by breast cancer survivors read more read less

Topics:

Breast cancer (63%)63% related to the paper
527 Citations
Journal Article DOI: 10.1007/S12032-010-9515-2
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu1, Jianan Huang1, Ying Chen, Cheng Chen1, Xueguang Zhang1
01 Sep 2011 - Medical Oncology

Abstract:

The immunohistochemical analysis was used to evaluate the expression of PD-L1 in 109 non-small cell lung cancer (NSCLC) tissues and para-tumor tissues. Associations between expressed PD-L1 and tumor histological types, degree of differentiation, and lymph node metastasis were calculated, and overall survival was assessed. Mea... The immunohistochemical analysis was used to evaluate the expression of PD-L1 in 109 non-small cell lung cancer (NSCLC) tissues and para-tumor tissues. Associations between expressed PD-L1 and tumor histological types, degree of differentiation, and lymph node metastasis were calculated, and overall survival was assessed. Meanwhile, immunohistochemistry and immunofluorescence double labeling technique were performed to detect the expressions of PD-L1, CD1α, and CD83 on TIDC of 20 lung cancer tissues, and the expression of PD-L1 in CD1α+DCs and CD83+DCs and their significances were also explored. We found that the expression rate of PD-L1 in NSCLC was associated with histological types and overall survival. Patients with either adenocarcinoma or survival time after surgery less than 3 years showed higher expression rate of PD-L1. Furthermore, Cox model analysis indicated that PD-L1 might be regarded as a poor prognostic factor. PD-L1 could be also detected in CD1α+ immature DC in NSCLC, indicating that as a class of key anti-tumor immunocyte in tumor microenvironment, DC expressing PD-L1 itself might play an important role in keeping its immature status and contributing to tumor cells immune escape and disease progression. read more read less

Topics:

Tumor microenvironment (57%)57% related to the paper, Lung cancer (55%)55% related to the paper, Adenocarcinoma (53%)53% related to the paper, PD-L1 (52%)52% related to the paper
520 Citations
Journal Article DOI: 10.1385/MO:18:4:243
Treatment resistance of solid tumors: role of hypoxia and anemia.
Peter Vaupel1, Oliver Thews1, Michael Hoeckel2
01 Jan 2001 - Medical Oncology

Abstract:

Hypoxia is a characteristic property of locally advanced solid tumors, resulting from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the development of hypoxia are (1) structural and functional abnormalities of the tumor microvasculature, (2) increased diffusion distances, and (3)... Hypoxia is a characteristic property of locally advanced solid tumors, resulting from an imbalance between the supply and consumption of oxygen. Major pathogenetic mechanisms for the development of hypoxia are (1) structural and functional abnormalities of the tumor microvasculature, (2) increased diffusion distances, and (3) tumor-associated and therapy-induced anemia. The oxygenation status is independent of clinical tumor size, stage, grade, and histopathological type, but is affected by the hemoglobin level. Hypoxia is intensified in anemic patients, especially in tumors with low perfusion rates. Hypoxia and anemia (most probably via worsening of tumor hypoxia) can lead to therapeutic problems, as they make solid tumors resistant to sparsely ionizing radiation and some forms of chemotherapy. In addition to more direct mechanisms involved in the development of therapeutic resistance, there are also indirect machineries that can cause barriers to therapies. These include hypoxia-driven proteome and genome changes and clonal selection. These, in turn, can drive subsequent events that are known to further increase resistance to therapy (in addition to critically affecting long-term prognosis). Treatment resistance in anemic patients can be, at least partially, prevented or overcome by anemia correction, resulting in better locoregional tumor control and overall survival of patients. read more read less

Topics:

Tumor hypoxia (59%)59% related to the paper, Hypoxia (medical) (55%)55% related to the paper, Tumor Oxygenation (52%)52% related to the paper, Anemia (51%)51% related to the paper
490 Citations
Journal Article DOI: 10.1007/S12032-011-9846-7
Metformin and cancer: new applications for an old drug
Taxiarchis Kourelis1, Robert D. Siegel2
01 Jun 2012 - Medical Oncology

Abstract:

Metformin, one of most widely prescribed oral hypoglycemic agents, has recently received increased attention because of its potential antitumorigenic effects that are thought to be independent of its hypoglycemic effects. Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth i... Metformin, one of most widely prescribed oral hypoglycemic agents, has recently received increased attention because of its potential antitumorigenic effects that are thought to be independent of its hypoglycemic effects. Several potential mechanisms have been suggested for the ability of metformin to suppress cancer growth in vitro and vivo: (1) activation of LKB1/AMPK pathway, (2) induction of cell cycle arrest and/or apoptosis, (3) inhibition of protein synthesis, (4) reduction in circulating insulin levels, (5) inhibition of the unfolded protein response (UPR), (6) activation of the immune system, and (7) eradication of cancer stem cells. There is also a growing number of evidence, mostly in the form of retrospective clinical studies that suggest that metformin may be associated with a decreased risk of developing cancer and with a better response to chemotherapy. There are currently several ongoing randomized clinical trials that incorporate metformin as an adjuvant to classic chemotherapy and aim to evaluate its potential benefits in this setting. This review highlights basic aspects of the molecular biology of metformin and summarizes new advances in basic science as well as intriguing results from recent clinical studies. read more read less

Topics:

Metformin (56%)56% related to the paper, Cancer (51%)51% related to the paper
273 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Medical Oncology.

It automatically formats your research paper to Springer formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Medical Oncology in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Medical Oncology guidelines and auto format it.

2. Do you follow the Medical Oncology guidelines?

Yes, the template is compliant with the Medical Oncology guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Medical Oncology?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Medical Oncology citation style.

4. Can I use the Medical Oncology templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Medical Oncology.

5. Can I use a manuscript in Medical Oncology that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Medical Oncology that you can download at the end.

6. How long does it usually take you to format my papers in Medical Oncology?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Medical Oncology.

7. Where can I find the template for the Medical Oncology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Medical Oncology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Medical Oncology's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Medical Oncology an online tool or is there a desktop version?

SciSpace's Medical Oncology is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Medical Oncology?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Medical Oncology?”

11. What is the output that I would get after using Medical Oncology?

After writing your paper autoformatting in Medical Oncology, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Medical Oncology's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Medical Oncology?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Medical Oncology. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Medical Oncology?

The 5 most common citation types in order of usage for Medical Oncology are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Medical Oncology?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Medical Oncology's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Medical Oncology in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Medical Oncology Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Medical Oncology formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template